報價延遲最少15分鐘:2025/01/21 18:53 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.1 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.34/-0.30
|
|
企業價值
539.05M
|
| 資產負債 |
|
每股賬面淨值
2.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
41.29M
|
|
每股收益
0.39
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:53 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |